Amneal Pharmaceuticals has agreed to acquire biopharma firm Kashiv BioSciences in a cash-and-stock deal ​worth up to $1.1 billion that will expand ‌the drugmaker's biosimilars business.

President Trump's new executive order has drawn major attention to psychedelic treatments for mental health. Here's what ...

A booming online marketplace exists for alternatives to popular weight-loss medications. But these drugs can be risky.

President Trump has signed an executive order to make certain psychedelic drugs more available to treat mental health ...

Eli Lilly & Co. agreed to buy sleep drug maker Centessa Pharmaceuticals Plc in a deal worth up to $7.8 billion, a sign the weight-loss medication giant is looking to bulk up its treatment pipeline for ...

Novartis NOVN0.18%increase; green up pointing triangle said it agreed to buy biotech company Excellergy for up to $2 billion, adding a new approach to treat allergic diseases to its immunology ...

Someone used a government credit card to make more than $28,000 of purchases online, the newly hired secretary shared during a city council meeting FOX 4 Dallas-Fort Worth/YouTube An unknown suspect ...

Novartis (NVS) has agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3B to support its oncology strategy in HR+/HER2- breast cancer. SNV4818 is an oral ...

Novartis NOVN-0.34%decrease; red down pointing triangle struck a deal valued at up to $3 billion to buy an experimental breast-cancer drug from Synnovation Therapeutics, moving to bolster its oncology ...

Novartis AG agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3 billion to bolster its oncology pipeline. The Swiss pharma company will pay the US biotech ...

Novartis struck a deal valued at up to $3 billion to buy an experimental breast-cancer drug from Synnovation Therapeutics, moving to bolster its oncology pipeline with a new treatment approach. The ...

FRANKFURT, March 20 (Reuters) - Swiss drugmaker ⁠Novartis ⁠on Friday agreed to ⁠buy a breast cancer drug candidate for up to $3 billion from U.S. biotech firm Synnovation Therapeutics, adding a ...